To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib.status: publishe
Abstract Objective C-reactive protein (CRP) is considered a useful serum marker for patients with RC...
359 Background: There are no established biomarkers predicting outcome of SUN treatment in mRCC.stat...
Aims: Patients with metastatic or inoperable kidney cancer with positive biomarkers of vascular endo...
To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in metastatic ren...
Objective: •To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in...
Background Sunitinib has become mainstay first line treatment for patients with metastatic renal cle...
ABSTRACT Purpose: To elucidate the prognostic value of systemic inflammatory response in patients w...
Introduction: Many factors influence the clinical course of patients with renal cell carcinoma (RCC)...
BACKGROUND:Growing evidence has revealed that pretreatment C-reactive protein to albumin ratio (CAR)...
High serum levels of the acute phase protein C-reactive protein (CRP) are associated with an adverse...
Selecting patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) who might benefit from ...
Background The dynamic change in C-reactive protein (CRP) levels, CRP kinetics, is a prognostic fact...
BACKGROUND: Several drugs are available to treat metastatic renal-cell carcinoma (MRCC), and predic...
BackgroundThe preoperative C-reactive protein/Albumin (CRP/Alb) ratio has been shown to be valuable ...
Two consecutive multi-center phase II trials were designed to prove the hypothesis, whether therapeu...
Abstract Objective C-reactive protein (CRP) is considered a useful serum marker for patients with RC...
359 Background: There are no established biomarkers predicting outcome of SUN treatment in mRCC.stat...
Aims: Patients with metastatic or inoperable kidney cancer with positive biomarkers of vascular endo...
To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in metastatic ren...
Objective: •To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in...
Background Sunitinib has become mainstay first line treatment for patients with metastatic renal cle...
ABSTRACT Purpose: To elucidate the prognostic value of systemic inflammatory response in patients w...
Introduction: Many factors influence the clinical course of patients with renal cell carcinoma (RCC)...
BACKGROUND:Growing evidence has revealed that pretreatment C-reactive protein to albumin ratio (CAR)...
High serum levels of the acute phase protein C-reactive protein (CRP) are associated with an adverse...
Selecting patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) who might benefit from ...
Background The dynamic change in C-reactive protein (CRP) levels, CRP kinetics, is a prognostic fact...
BACKGROUND: Several drugs are available to treat metastatic renal-cell carcinoma (MRCC), and predic...
BackgroundThe preoperative C-reactive protein/Albumin (CRP/Alb) ratio has been shown to be valuable ...
Two consecutive multi-center phase II trials were designed to prove the hypothesis, whether therapeu...
Abstract Objective C-reactive protein (CRP) is considered a useful serum marker for patients with RC...
359 Background: There are no established biomarkers predicting outcome of SUN treatment in mRCC.stat...
Aims: Patients with metastatic or inoperable kidney cancer with positive biomarkers of vascular endo...